Acorda Therapeutics Inc (ACOR): Steven M Rauscher , director of Acorda Therapeutics Inc sold 1,086 shares on Jun 8, 2016. The Insider selling transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were sold at $27.83 per share for a total value of $30,223.92 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, Andrew A. Hindman (Chief Business Dev. Officer) sold 4,860 shares at $26.11 per share price.On Apr 21, 2016, Lorin Randall (director) sold 1,488 shares at $28.68 per share price.Also, On Jan 6, 2016, Ian F Smith (director) sold 13,231 shares at $42.05 per share price.On Dec 28, 2015, Jane Wasman (President, Intl and GC) sold 10,751 shares at $43.10 per share price.
Shares of Acorda Therapeutics Inc (ACOR) ended Thursday, Jun 9, 2016 session in red amid volatile trading. The shares closed down -0.41 points or -1.47% at $27.52 with 2,51,855 shares getting traded. Post opening the session at $27.82, the shares hit an intraday low of $27.411 and an intraday high of $28.28 and the price vacillated in this range throughout the day. The company has a market cap of $1,268 M and the number of outstanding shares has been calculated to be 4,60,67,276 shares. The 52-week high of Acorda Therapeutics Inc is $43.63 and the 52-week low is $23.85.
Company has been under the radar of several Street Analysts.Acorda Therapeutics Inc is Initiated by Goldman to Sell. The Rating was issued on Mar 30, 2016.
Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinsons disease epilepsy heart failure MS and spinal cord injury.